(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 158.51% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Absci's revenue in 2025 is $4,815,000.On average, 4 Wall Street analysts forecast ABSI's revenue for 2025 to be $1,937,116,319, with the lowest ABSI revenue forecast at $714,332,371, and the highest ABSI revenue forecast at $4,275,789,479. On average, 4 Wall Street analysts forecast ABSI's revenue for 2026 to be $6,612,931,926, with the lowest ABSI revenue forecast at $1,428,664,742, and the highest ABSI revenue forecast at $9,822,070,104.
In 2027, ABSI is forecast to generate $10,430,017,976 in revenue, with the lowest revenue forecast at $9,311,832,696 and the highest revenue forecast at $11,653,822,399.